ES2168226B1 - Composicion que comprende sodio, potasio, calcio y magnesio. - Google Patents

Composicion que comprende sodio, potasio, calcio y magnesio.

Info

Publication number
ES2168226B1
ES2168226B1 ES200002833A ES200002833A ES2168226B1 ES 2168226 B1 ES2168226 B1 ES 2168226B1 ES 200002833 A ES200002833 A ES 200002833A ES 200002833 A ES200002833 A ES 200002833A ES 2168226 B1 ES2168226 B1 ES 2168226B1
Authority
ES
Spain
Prior art keywords
magnesium
potassium
calcium
source
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200002833A
Other languages
English (en)
Other versions
ES2168226A1 (es
Inventor
Escude Alfred Blasi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recuperat Ion Electrolitos S L
Original Assignee
Recuperat Ion Electrolitos S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200002833A priority Critical patent/ES2168226B1/es
Application filed by Recuperat Ion Electrolitos S L filed Critical Recuperat Ion Electrolitos S L
Priority to BR0115640-3A priority patent/BR0115640A/pt
Priority to US10/432,178 priority patent/US20040033272A1/en
Priority to PT01905835T priority patent/PT1338284E/pt
Priority to MXPA03004628A priority patent/MXPA03004628A/es
Priority to DE60123464T priority patent/DE60123464T2/de
Priority to ES01905835T priority patent/ES2273805T3/es
Priority to AU2001233812A priority patent/AU2001233812A1/en
Priority to AT01905835T priority patent/ATE340583T1/de
Priority to PCT/ES2001/000067 priority patent/WO2002041905A1/es
Priority to EP01905835A priority patent/EP1338284B1/en
Publication of ES2168226A1 publication Critical patent/ES2168226A1/es
Application granted granted Critical
Publication of ES2168226B1 publication Critical patent/ES2168226B1/es
Priority to US11/622,882 priority patent/US20070116780A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición que comprende sodio, potasio, calcio y magnesio. La composición comprende una fuente de sodio, una fuente de potasio, una fuente de calcio y una fuente de magnesio, que comprenden compuestos de sodio, potasio, calcio y magnesio, fisiológicamente aceptables, solubles o dispersables en un medio acuoso que, en solución o dispersión en dicho medio acuoso proporcionan iones de dichos elementos. La composición es útil en el tratamiento de enfermedades de etiología muscular, neuromuscular u ósea, así como en el tratamiento de estados carenciales o deficitarios en dichos elementos, y en la recuperación muscular de personas y animales sanos.
ES200002833A 2000-11-27 2000-11-27 Composicion que comprende sodio, potasio, calcio y magnesio. Expired - Fee Related ES2168226B1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES200002833A ES2168226B1 (es) 2000-11-27 2000-11-27 Composicion que comprende sodio, potasio, calcio y magnesio.
AT01905835T ATE340583T1 (de) 2000-11-27 2001-02-22 Zusammensetzung aus natrium, kalium, calcium und magnesium
PT01905835T PT1338284E (pt) 2000-11-27 2001-02-22 Composição compreendendo sódio, potássio, cálcio e magnésio
MXPA03004628A MXPA03004628A (es) 2000-11-27 2001-02-22 Composiciones que comprende sodio, potasio, calcio y magnesio.
DE60123464T DE60123464T2 (de) 2000-11-27 2001-02-22 Zusammensetzung aus natrium, kalium, calcium und magnesium
ES01905835T ES2273805T3 (es) 2000-11-27 2001-02-22 Composicion que comprende sodio, potasio, calcio y magnesio.
BR0115640-3A BR0115640A (pt) 2000-11-27 2001-02-22 Composição compreendendo sódio, potássio, cálcio e magnésio
US10/432,178 US20040033272A1 (en) 2000-11-27 2001-02-22 Composition comprising sodium, potassium, calcium and magnesium
PCT/ES2001/000067 WO2002041905A1 (es) 2000-11-27 2001-02-22 Composición que comprende sodio, potasio, calcio y magnesio
EP01905835A EP1338284B1 (en) 2000-11-27 2001-02-22 Composition comprising sodium, potassium, calcium and magnesium
AU2001233812A AU2001233812A1 (en) 2000-11-27 2001-02-22 Composition comprising sodium, potassium, calcium and magnesium
US11/622,882 US20070116780A1 (en) 2000-11-27 2007-01-12 Composition comprising sodium, potassium, calcium and magnesium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200002833A ES2168226B1 (es) 2000-11-27 2000-11-27 Composicion que comprende sodio, potasio, calcio y magnesio.

Publications (2)

Publication Number Publication Date
ES2168226A1 ES2168226A1 (es) 2002-06-01
ES2168226B1 true ES2168226B1 (es) 2003-09-16

Family

ID=8495772

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200002833A Expired - Fee Related ES2168226B1 (es) 2000-11-27 2000-11-27 Composicion que comprende sodio, potasio, calcio y magnesio.
ES01905835T Expired - Lifetime ES2273805T3 (es) 2000-11-27 2001-02-22 Composicion que comprende sodio, potasio, calcio y magnesio.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01905835T Expired - Lifetime ES2273805T3 (es) 2000-11-27 2001-02-22 Composicion que comprende sodio, potasio, calcio y magnesio.

Country Status (10)

Country Link
US (2) US20040033272A1 (es)
EP (1) EP1338284B1 (es)
AT (1) ATE340583T1 (es)
AU (1) AU2001233812A1 (es)
BR (1) BR0115640A (es)
DE (1) DE60123464T2 (es)
ES (2) ES2168226B1 (es)
MX (1) MXPA03004628A (es)
PT (1) PT1338284E (es)
WO (1) WO2002041905A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1795202A1 (en) * 2005-12-07 2007-06-13 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Preparation for treatment of mineral deficiency
EP1996034A4 (en) * 2006-02-28 2011-12-07 David R Beeman WATER FORMULATION
CA2682200C (en) 2007-03-19 2015-01-13 Vita Sciences, Llc Transdermal patch and method for delivery of vitamin b12
EP2247197B1 (en) * 2008-02-06 2012-11-07 Campbell Soup Company Methods and compositions for reducing sodium content in food products
US8192745B2 (en) * 2010-01-11 2012-06-05 Madere Shawn P Nutritional supplement to improve supplementary target protein fraction (TPF) delivery, intracellular absorption and utilization
IL247130B (en) * 2015-08-06 2021-06-30 Kenneth Davin Fine A compound for blocking and absorbing oxalate for use in the treatment of pain due to fibromyalgia, calcification of the spinal cord and calcification of the shoulder
EP3693020A1 (en) * 2019-02-08 2020-08-12 Burmaster International Group GmbH Potassium enriched topical formulations for pain relief and sleep aid
ES2949880A1 (es) * 2022-02-27 2023-10-03 Vidal Miquel Gonzalez Medicamento natural para el tratamiento de hemorroides y posologia de aplicacion

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1998179A (en) * 1930-12-27 1935-04-16 Wolf Eduard Julius Physiologically balanced salt mixture
JPS5632411A (en) * 1979-08-27 1981-04-01 Tomita Seiyaku Kk Preparation of perfusion liquid for artificial kidney dialysis
US4975419A (en) * 1988-09-09 1990-12-04 Entravision, Inc. Tissue irrigating solution
CA2080818A1 (en) * 1990-05-16 1991-11-17 Zbigniew Walaszek Formula and method for the prevention and treatment of hypercholesterolemia and cellular hyerproliferative disorders
US5460972A (en) * 1991-04-08 1995-10-24 Research Foundation Of The State University Of New York Ionized magnesium2+ concentrations in biological samples
EP0587972A1 (en) * 1992-09-18 1994-03-23 The Procter & Gamble Company Sports drink without added sugar or artificial sweetener
US5397786A (en) * 1993-01-08 1995-03-14 Simone; Charles B. Rehydration drink
FR2731620B1 (fr) * 1995-03-13 1997-06-06 Drouault Guy Compositions pharmaceutiques pour la regulation de la polarisation des muscles lisses unitaires
AT408416B (de) * 1996-07-19 2001-11-26 Norbert Fuchs Pharmazeutische bzw. diätetische zusammensetzungen
FI120290B (fi) * 1996-12-30 2009-09-15 Mirador Res Oy Ltd Menetelmä, jonka avulla voidaan valmistaa sellaisia mausteseos-, ruoan ainesosa- ja elintarvikekoostumuksia, jotka alentavat seerumin kolesterolia
FR2773955B1 (fr) * 1998-01-26 2000-04-07 Sanofi Sa Composition dietetique sous forme d'un sel de substitution du sel de table
JP2000060506A (ja) * 1998-08-21 2000-02-29 Ogiwara Fumitake 添加用高濃度ミネラル溶液の組成及びその製法
US6541050B1 (en) * 1998-11-27 2003-04-01 Campbell Soup Company Salt flavor enhancing compositions, food products including such compositions, and methods for preparing such products
NL1010786C1 (nl) * 1998-12-11 2000-06-19 United Soft Drinks B V Een zoutenbevattende drank en werkwijze voor de bereiding ervan.

Also Published As

Publication number Publication date
ES2168226A1 (es) 2002-06-01
EP1338284A1 (en) 2003-08-27
DE60123464T2 (de) 2007-08-02
US20070116780A1 (en) 2007-05-24
ATE340583T1 (de) 2006-10-15
MXPA03004628A (es) 2004-10-14
BR0115640A (pt) 2004-02-03
PT1338284E (pt) 2007-01-31
DE60123464D1 (de) 2006-11-09
ES2273805T3 (es) 2007-05-16
US20040033272A1 (en) 2004-02-19
AU2001233812A1 (en) 2002-06-03
WO2002041905A1 (es) 2002-05-30
EP1338284B1 (en) 2006-09-27

Similar Documents

Publication Publication Date Title
ATE297723T1 (de) Pharmazeutische zusammensetzung enthaltend ein 5- aminolaevulinsäure-ester als photochemotherapeutikum und ein mucoadhäsivum
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
BRPI0519195A2 (pt) composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal
HK1103363A1 (en) Treatment of glycogen storage diseases type ii ii
WO2001092283A3 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
AU7566601A (en) Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases
DE69827143D1 (de) Wässerige alkalimetallbicarbonat-lösungen zur benahdlung von osteoarthrose
DE60036014D1 (de) Methode zur stabilisierung von benzimidazol-verbindungen
EA200501690A1 (ru) Композиция, включающая ингибитор pde4 и ингибитор pde5
DK1401422T3 (da) Halogenholdig sammensætning, fremgangsmåde til fremstilling heraf og anvendelser heraf
NO994431L (no) Ny formulering
ES2168226B1 (es) Composicion que comprende sodio, potasio, calcio y magnesio.
EP1485096A4 (en) METHODS FOR PREVENTING OR TREATING HEART ARRHYTHMIA
ATA130496A (de) Pharmazeutische bzw. diätetische zusammensetzungen
WO2001089520A3 (en) Dehydroascorbic acid formulations and uses thereof
BR9906926A (pt) Composições e métodos para tratamento de células tendo dna de minuto duplo
HRP20050534A2 (en) Prevention and treatment of alzheimer's disease
BR9915729A (pt) Amidas Èmega de n-arilsulfonil-aminoácido
EP1254260A4 (en) METHODS FOR DIAGNOSING AND TREATING A HEART DISEASE
AU2979899A (en) Treatment of viral disease in swine
ATE172106T1 (de) Orale zusammensetzungen mit verbesserter stabilität, welche natrium-carbonat und bicarbonat-salz enthalten
NO20032411L (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens
PT1581239E (pt) Utilização precoce de um extracto de folhas de videira vermelha
WO2002015894A3 (en) Use of vitamin d derivatives as bone resorption inhibitors

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020601

Kind code of ref document: A1

Effective date: 20020601

PC2A Transfer of patent
FG2A Definitive protection

Ref document number: 2168226B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20210309